Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for allegedly misleading investors regarding its accounts receivable and financial reporting practices [1][2]. Group 1: Allegations - Ardent Health reportedly inflated its accounts receivable and delayed recognizing losses on uncollectable accounts during the class period [2]. - The company did not maintain sufficient professional malpractice liability insurance to cover claims arising from its operations [2]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised assessments of accounts receivable collectability, leading to a significant stock price drop of nearly 34% [2]. Group 2: Legal Proceedings - Shareholders who purchased Ardent Health securities between July 18, 2025, and November 12, 2025, may be eligible to participate in the class action [1][3]. - Interested shareholders can contact Robbins LLP to serve as lead plaintiff, representing other class members in the litigation [3]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Ardent Health, Inc. following significant adverse accounting adjustments of approximately $90 million, leading to a stock price decline of over 33% [1] Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired Ardent securities between July 18, 2024, and November 12, 2025 [1] - The lead plaintiff deadline for the lawsuit is set for March 9, 2026 [3] - The case is titled Postiwala v. Ardent Health, Inc. et al., No. 3:26-cv-00022 (M.D. Tenn.) [3] Group 2: Allegations and Investigations - Hagens Berman is investigating claims that Ardent's leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves [2] - The complaint alleges that timely writing off uncollectible accounts is crucial to avoid inflating accounts receivable [4] - The lawsuit claims that Ardent misled investors regarding its reliance on detailed reviews of historical collections for determining accounts receivable collectability [5] Group 3: Financial Disclosures and Market Reaction - On November 12, 2025, Ardent disclosed a $42.6 million decrease in revenue due to changes in accounting estimates and new information from hindsight evaluations [6] - The CFO revealed that the company's collectability framework used a 180-day cliff for reserving accounts, contradicting earlier assurances [6] - Following the disclosures, Ardent's stock price fell by $4.75, a decline of 33% [6] Group 4: Implications and Further Actions - The significant revenue reduction of $43 million and reserve increase of $54 million raises questions about whether these issues should have been disclosed earlier [7] - Investors who suffered losses are encouraged to contact Hagens Berman for potential recovery options [7]

Core Viewpoint - A class action has been filed against Fermi Inc. for allegedly misleading investors regarding its business prospects, particularly related to its Project Matador campus [1][2]. Allegations - Fermi Inc. is accused of failing to disclose that it overstated tenant demand for its Project Matador campus [2] - The company did not adequately inform investors about its reliance on a single tenant's funding commitment for the construction of Project Matador [2] - There was a significant risk that the tenant could terminate its funding commitment, which was not disclosed to investors [2] Stock Price Impact - On December 12, 2025, Fermi announced that the first tenant for Project Matador had terminated a $150 million funding agreement, leading to a stock price drop of $5.16 per share, or 33.8%, closing at $10.09 [3] - By the time of the class action announcement, Fermi's stock had traded as low as $8.59 per share, representing a 59% decline from the IPO price of $21.00 per share [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by March 6, 2026, but participation is not required for recovery [4] - Shareholders can remain absent class members if they choose not to take action [4] Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5]

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Firefly Aerospace Inc. ("Firefly†or the "Company†) (NASDAQ:FLY) investors of the January 12, 2026 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Firefly securities between August 4, 2025 through September 29, 2025 ("the Class Period†). 22, 2025 earnings call that the Company "expect[ed] to launch Flight 7 in the coming weeks.†Following on the heels of Firefly's failed April 2 ...

Group 1 - The core point of the news is that SelectQuote, Inc. is facing a securities class action lawsuit for failing to disclose material information during the class period from September 9, 2020, to May 1, 2025, with a deadline for lead plaintiff applications set for October 10, 2025 [1][3] - The U.S. Department of Justice filed a complaint against SelectQuote on May 1, 2025, alleging that the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to at least 2021, which led to a significant drop in the company's stock price by 19.2% to $2.56 per share on the same day [4] - ClaimsFiler is a service that assists retail investors in recovering funds from securities class action settlements, providing resources for investors to register, upload transactional data, and seek legal evaluations [5][6] Group 2 - The lawsuit against SelectQuote includes allegations of conspiracy with major insurers to discriminate against less profitable Medicare beneficiaries and making materially false claims regarding unbiased coverage comparisons [4] - Investors affected by the lawsuit are encouraged to visit ClaimsFiler's website or contact the law firm Kahn Swick & Foti, LLC for legal assistance [2]

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period [1][2]. Group 1: Allegations and Company Performance - The complaint alleges that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), specifically that it lacked sufficient details on chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - Following the announcement of a refusal to file (RTF) letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [3]. Group 2: Legal Proceedings and Participation - Shareholders may be eligible to participate in the class action against Savara Inc., with the option to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its revenue projections and the impact of its CEO's health on operations [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased C3's securities between February 26, 2025, and August 8, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against C3.ai - The complaint alleges that C3.ai made false and misleading statements that led investors to believe the company could reliably project its revenues and growth [4]. - The company downplayed the risks associated with the health concerns of CEO Thomas M. Siebel, which ultimately affected its optimistic projections for growth, earnings, and margins [4]. - When the truth about C3's operations and the impact of the CEO's health became known, investors suffered damages [4].

Core Viewpoint - A securities class action lawsuit has been filed against SelectQuote following the U.S. Department of Justice's intervention in a separate lawsuit, leading to a significant 19% drop in the company's stock price on May 1, 2025 [1][4]. Group 1: Lawsuit Details - The class action, Pahlkotter v. SelectQuote, Inc. et al., seeks to represent investors who acquired SelectQuote securities between September 9, 2020, and May 1, 2025 [2]. - The lead plaintiff deadline for the lawsuit is set for October 10, 2025 [2]. Group 2: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements regarding its business practices, particularly in its Medicare Advantage sales [3]. - The DOJ claims that from 2016 to at least 2021, SelectQuote received "tens of millions of dollars" in illegal kickbacks for directing Medicare beneficiaries to specific plans, contradicting its claims of providing unbiased advice [3][8]. - The company allegedly discriminated against less profitable beneficiaries and directed customers to the highest-paying plans, which raises concerns about compliance with applicable laws [3][8]. Group 3: Impact on Stock and Investor Sentiment - Following the announcement of the DOJ's involvement and the class action lawsuit, SelectQuote's stock price has continued to decline, indicating a significant impact on the company's market value [4]. - Hagens Berman is investigating the extent to which SelectQuote's alleged practices may have inflated its financial results, leading to investor losses [7][9].

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including its gene therapy product, ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, inadequate trial protocols to detect severe side effects, and the potential for adverse events to halt clinical trials and regulatory approvals [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

Core Viewpoint - West Pharmaceutical Services, Inc. is facing a federal securities class action due to disappointing revenue and earnings forecasts, attributed to operational challenges and customer losses during the Class Period from February 16, 2023, to February 12, 2025 [1][3]. Group 1: Financial Performance and Forecasts - On February 13, 2025, West issued weak revenue and earnings forecasts for 2025, citing challenges including the loss of two major continuous glucose monitoring (CGM) customers transitioning to in-house manufacturing [3]. - The company's share price dropped by approximately 38%, from $322.28 on February 12, 2025, to $199.11 on February 13, 2025, following the announcement [3]. Group 2: Allegations in the Class Action - The complaint alleges that West failed to disclose significant destocking issues in its high-margin HVP portfolio, contrary to claims of strong visibility into customer demand [4]. - It is claimed that the SmartDose device, positioned as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [4]. - The margin pressures faced by West raised concerns about potential costly restructuring activities, including exiting CGM contracts with long-standing customers [4].